The nation of Zimbabwe has declined a substantial US healthcare agreement worth $367m (£272m) spanning five years because of the United States' demand for confidential information.
The decision became public following a government memo dated December was disclosed, revealing that President Emmerson Mnangagwa deemed the agreement was "lopsided".
A government spokesperson later explained that the US was seeking genetic material for research and commercial gain but was not willing to guarantee the benefits from any future medical innovations.
"We are forced to start the difficult and regrettable process of ending our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had donated over $1.9bn for health programmes to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has appealed for further talks to reach a agreement agreeable to all parties so the country's vital HIV programme can continue.
Broader Implications
Zimbabwe's decision comes after a similar case in Kenya, where a court suspended a related health funding agreement after legal challenges were raised about the security of citizens' health data.
Since returning to the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump argued its spending was "wasteful" and his administration was seeking direct bilateral deals to enhance openness and responsibility.
Based on statements, Sixteen nations in Africa have to date agreed to similar agreements, constituting more than $18.3bn in new funding.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership might have yielded immense advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on antiretroviral therapy through US-supported programmes," the Ambassador said.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"Zimbabwe was being asked to share its genetic material and health information over an extended period, without any equivalent promise of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," his statement read.
"Effectively, our nation would provide the raw materials for medical research without any certainty that the end products would be accessible to our citizens should a new disease outbreak emerge."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral deals were undermining frameworks already established via the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing framework created to deal with future global health emergencies.
"This system is designed to ensure that when a nation provides its samples, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the resources to create them."
These objections over the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We welcome ongoing dialogue with our American counterparts on how future collaboration could be structured in a manner that honours the independence and dignity of both nations."
Health Experts Reaction
Medical experts said it understood the government's concerns, but urged that talks need to persist considering much of the nation's Aids initiatives depended on external financing.
"In cases where technical issues exist, including those involving data governance or agreement terms, these can frequently be resolved via detailed discussion and mutually agreed protections," the group commented.
The halted deal underscores the ongoing challenges between receiving much-needed international aid and safeguarding national sovereignty in an ever more data-driven world.